Erratum: Consensus guideline on parental methadone use in pain and palliative care (Palliative and Supportive Care (2008) vol. 6 (2) (165-176) 10.1017/S1478951508000254);Consensus guideline on parenteral methadone use in pain and palliative care

Palliative and Supportive Care

Volumn 6, Issue 2, 2008, Pages 165-176

  Shaiova, Lauren ^a,k   Berger, Ann ^b   Blinderman, Craig D ^c   Bruera, Eduardo ^d   Davis, Mellar P ^e   Derby, Susan ^f   Inturrisi, Charles ^g   Kalman, Jill ^h   Mehta, Davendra ⁱ   Pappagallo, Marco ^j   Perlov, Eugene ^e  

^a Pain and Palliative Care Physician   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g MOUNT SINAI MEDICAL CENTER   (United States)

^h MOUNT SINAI HOSPITAL   (United States)

ⁱ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^j VISITING NURSE SERVICE OF NEW YORK   (United States)

^k METROPOLITAN HOSPITAL CENTER   (United States)

more..

Author keywords

Analgesia; Analgesics; Intravenous methadone; Opioid; Pain; Palliative care

Indexed keywords

EID: 44449128180     PISSN: 14789515     EISSN: 14789523     Source Type: Journal    
DOI: 10.1017/S1478951508000503     Document Type: Erratum

References (26)

1. Al-Khatib, S.M., LaPointe, N.M., Kramer, J.M., et al. (2003). What clinicians should know about QT interval. Journal of the American Medical Association, 289, 2120-2127.
2. Anderson, M.E., Al-Khatib, S.M., Roden, D.M., et al. (2002). Cardiac repolarization: Current knowledge, critical gaps, and new approaches to drug development and patient management. American Heart Journal, 144 769-781.
3. Auret, K., Roger Goucke, C., Ilett, K.F., et al. (2006). Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain. Therapeutic Drug Monitoring, 28 359-366.
4. Centeno, C. & Vara, F. (2005). Intermittent subcutaneous methadone administration in the management of cancer pain. Journal of Pain Palliative Care Pharmacotherapy, 19(2), 7-12.
5. Derby, S., Chin, J., & Portenoy, R.K. (1998). Systemic opioid therapy for chronic cancer pain: Practical guidelines for converting drugs and routes of adminsistration. CNS Drugs, 9, 99-109.
6. Drug Facts and Comparisons. (2007), p. 1082. St. Louis: Wolters-Kluwer Health.
7. Dyer, K.R. & White, J.M. (1997). Patterns of symptoms complaints in methadone maintenance patients. Addiction, 92, 1445-1455.
8. Ehret, G.B., Voide, C., Gex-Fabry, M., et al. (2006). Drug-induced long QT syndrome in injection drug users receiving methadone: High frequency in hospitalized patients and risk factors. Archives of Internal Medicine, 166, 1280-1287.
9. Fitzgibbon, D.R. & Ready, L.B. (1997). Intravenous high-dose methadone administered by patient controlled analgesia and continuous infusion for the treatment of cancer pain refractory to high-dose morphine. Pain, 73, 259-261.
10. Garson, A., Jr. (1993) How to measure the QT interval - What is normal. American Journal of Cardiology, 72, 14B-16B.
11. Kornick, C.A., Kilborn, M.J., Santiago-Palma, J., et al. (2003). QTc interval prolongation associated with intravenous methadone. Pain, 105, 499-506.
12. Krantz, M.J. & Mehler, P.S. (2006) QTc prolongation: Methadone's efficacy-safety paradox. Lancet, 368, 556-557.
13. Lawlor, P.G., Turner, K.S., Hanson, J., et al. (1998). Dose ratio between morphine and methadone in patients with cancer pain: A retrospective study. Cancer, 82, 1167-1173.
14. Makin, M.K. (2000). Subcutaneous methadone in terminally-ill patients [letter]. Journal of Pain and Symptom Management, 19, 237-238.
15. Manfredi, P.L., Borsook. D., Chandler, S.W., et al. (1997). Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: Clinical observations. Pain, 70, 99-101.
16. Manfredi, P.L. & Houde, R.W. (2003). Prescribing methadone, a unique analgesic. Journal of Supportive Oncology, 1, 216-220.
17. Mathew, P. & Storey, P. (1999). Subcutaneous methadone in terminally ill patients: Manageable local toxicity. Journal of Pain and Symptom Management, 18, 49-52.
18. Mercadante, S., Casuccio, A., & Calderone, L. (1999). Rapid switching from morphine to methadone in cancer patients with poor response to morphine. Journal of Clinical Oncology, 17, 1-6.
19. Morley, J.S. & Makin, M.K. (1998). The use of methadone in cancer pain poorly responsive to other opioids. Pain Reviews, 5, 51-58.
20. Moss, A.J., Zareba. W., Benhorin, J., et al. (2001). ISHNE guidelines for electrocardiographic evaluation of drug-related QT prolongation and other alterations in ventricular repolarization: Task force summary. A report of the Task Force of the International Society for Holter and Noninvasive Electrocardiology (ISHNE), Committee on Ventricular Repolarization. Annals of Noninvasive Electrocardiology, 6, 333-341.
21. Payne, R. & Inturrisi, C.E. (1985). CSF distribution of morphine, methadone and sucrose after intrathecal injection. Life Sciences, 37 1137-1144.
22. Ripamonti, C., De Conno, F., Groff, L., et al. (1998). Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: Comparison of two clinical experiences. Annals of Oncology, 9, 79-83.
23. Roden, D.M. (2004). Drug-induced prolongation of the QT interval. New England Journal of Medicine, 350, 1013-1022.
24. Santiago-Palma, J., Khojainova, N., Kornick, C., et al. (2001). Intravenous methadone in the management of chronic cancer pain: Safe and effective starting doses when substituting methadone for fentanyl. Cancer, 92, 1919-1925.
25. Sekine, R., Eugenia, A.M.T., Coyle, N., et al. (2007). The successful use of parenteral methadone in a patient with a prolonged QTc interval. Journal of Pain and Symptom Management, 34, 566-569.
26. Shaiova, L. (2006). The role of methadone in the treatment of moderate to severe cancer pain. Supportive Cancer Therapy, 2, 1-5.